European Commission Announces Participation in Framework to Deliver Corona Virus Vaccines Fairly September 1 at 6:46 AM
The European Commission, the executive body of the EU-European Union, announced its participation in a framework launched by the World Health Organization and others last month to fairly deliver vaccines for the new coronavirus to countries around the world. In this regard, WHO Director General Tedros indicated that he would continue to work with countries and other countries to make vaccines fairly available to all countries.
As of last month, 172 countries and regions, including Japan, the United Kingdom, and Canada, have shown interest in a cooperative system to promote the fair distribution of vaccines launched by WHO and others, but the United States, where vaccine development is active, has not participated.
Against this end, the European Commission announced its participation in the cooperation system and announced that it would contribute EUR 400 million and approximately 50.5 billion yen in Japanese yen.
In response, WHO Director General Tedros welcomed the decision at a regular press conference last month at its headquarters in Geneva, Switzerland, and said, “The only way to beat the global pandemic is to work together. Once vaccines are developed, we will continue to work with countries and other countries to ensure that all countries are fairly available.”
Who says it needs to confirm its intention by September 18 to participate in this cooperation system, and will continue to negotiate with countries that have not expressed interest.
What is the COVAX Facility?
The COVAX Facility is an international cooperation system jointly launched by who and international organizations working on vaccinations in developing countries, in which participating countries share costs for the discovery, manufacture, and fair distribution of effective vaccines.
The European Commission, the executive body of the EU-European Union, has announced its participation in this cooperation.
WHO and others are working together to prepare for mass production of vaccines from this stage so that they can begin supplying vaccines as soon as they are confirmed.
Specifically, with the aim of manufacturing 2 billion vaccines by the end of next year, the company aims to allow 20 percent of the population to receive vaccines in each country in which it invests, and that the equivalent vaccines will be distributed preferentially to medical professionals and other countries receiving support.